The HDAC inhibitor, Vorinostat (SAHA, developed by Merck) has not only been approved as a treatment agent for T‐cell lymphoma but is also undergoing phase 2 and 3 clinical trials for breast cancer and non‐small cell lung cancer.43 This evidence concerns the gene HDAC9 and lung cancer.